Physician profile
Daniel Brownstone
NPI 1942204599
$3,075.57
in general payments reported to CMS, 2019-2025
24 companies · $579 in 2025
The $579 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $146 · 2021: $404 · 2022: $421 · 2023: $538 · 2024: $645 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $392.60 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $348.34 | 2021-2025 | Acthar |
| Alcon Vision LLC | $275.80 | 2021-2025 | Rocklatan, Clareon, Tryptyr |
| Abbvie INC. | $211.11 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Rxsight INC | $187.68 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $183.64 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $179.97 | 2019-2021 | |
| Oyster Point Pharma, INC. | $174.84 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Harrow Eye, LLC | $160.96 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $132.19 | 2019-2025 | Cequa |
| Glaukos Corporation | $131.37 | 2022-2024 | Ce-Marked Kxla System, Kxl System (Not Refurbished), Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $130.96 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $115.46 | 2022-2025 | Vyzulta |
| Amgen INC. | $93.15 | 2024-2025 | Tepezza |
| Astellas Pharma US INC | $79.39 | 2024-2025 | Izervay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $66.02 | 2022-2023 | Vabysmo |
| Shire North American Group INC | $42.57 | 2019 | |
| Thea Pharma INC. | $38.05 | 2023-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $27.64 | 2019-2020 | |
| Dompe US, INC. | $24.91 | 2024 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $24.62 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $20.95 | 2022 | |
| Horizon Therapeutics Plc | $20.90 | 2021 | |
| Kala Pharmaceuticals, INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brownstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.